Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 8/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.58 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299143 | 0.98 | HPGD (0.58) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL1299658 | 0.96 | HPGD (0.59) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL10906512 | 0.96 | HPGD (0.59) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL3067625 | 0.95 | PARP15 (0.54) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL3718600 | 0.94 | PARP15 (0.54) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL8314306 | 0.94 | PARP15 (0.54) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL8312964 | 0.94 | PARP15 (0.54) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL22820830 | 0.89 | PARP15 (0.50) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL28371333 | 0.86 | ALDH1A1 (0.50) | PARP15PARP10PARP2HPGDALDH1A1 | |
| SCHEMBL1299517 | 0.86 | HPGD (0.61) | PARP15PARP10PARP2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2881384-B1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| EP-2881384-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| WO-2004087125-A1 | AMINO ACID DERIVATIVES AS INHIBITORS OF MAMMALIAN SODIUM CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | PARP15 1715/4885PARP10 1539/4885PARP2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.